Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received October 18, 2011
- Accepted January 31, 2012
- First Published May 9, 2012.
Article Versions
- Previous version (May 9, 2012 - 13:02).
- You are viewing the most recent version of this article.
Author Disclosures
- S.E. Bushnell, PhD,
- Z. Zhao, MS, MMed,
- C.C. Stebbins, PhD,
- D. Cadavid, MD,
- A.M. Buko, PhD,
- E.T. Whalley, PhD,
- J.A. Davis, BS,
- E.M. Versage, MA,
- J.R. Richert, MD,
- R.C. Axtell, PhD,
- L. Steinman, MD and
- R. Medori, MD
- S.E. Bushnell, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Sr. Director Translational Medicine, Biogen Idec
NONE
NONE
NONE
NONE
Biogen Idec
NONE
NONE
NONE
NONE
NONE
NONE
Biogen Idec, 2012, 2011
Biogen Idec, 2012, 2011
NONE
- Z. Zhao, MS, MMed,
NONE
NONE
NONE
NONE
NONE
NONE
I am a full time employee of Biogen IDec.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- C.C. Stebbins, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
Biogen Idec, Sr. Scientist
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- D. Cadavid, MD,
NONE
NONE
NONE
NONE
NONE
NONE
I’m a full time paid employee of Biogen Idec and own restricted stock units and stock in Biogen Idec
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I own stock and restricted stock units as compensation for my full time employment at Biogen Idec
NONE
NONE
I own stock and have been awarded restricted stock units as compensation for my full time employment at Biogen Idec
NONE
NONE
- A.M. Buko, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- E.T. Whalley, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
I am an employee of Biogen Idec.
NONE
NONE
I own stock in Biogen Idec.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- J.A. Davis, BS,
I am employed by Biogen Idec, Inc.
NONE
NONE
Currently on the editorial board of the Journal of Neurotherapeutics. I do not receive compensation for this.
NONE
NONE
I am employed by Biogen Idec, Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am employed by Biogen Idec. Some of my compensation is in the form of stock options.
NONE
NONE
I am employed by Biogen Idec, Inc. Some of my compensation is in the form of stock options.
I am employed by Biogen Idec, In. Some of my compensation is in the form of stock options.
NONE
- E.M. Versage, MA,
NONE
NONE
NONE
NONE
NONE
NONE
Biogen Idec, Clinical Operations
NONE
NONE
I own stock in Biogen Idec.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- J.R. Richert, MD,
NONE
NONE
NONE
Journal of Neurotherapeutics
NONE
NONE
I am employed by Biogen Idec, Inc.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
I am employed by Biogen Idec, In. Some of my compensation is in the form of stock options.
NONE
- R.C. Axtell, PhD,
NONE
NONE
NONE
NONE
Patent on bio markers predicting response to ifnb treatment
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH-ninds
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- L. Steinman, MD and
NONE
NONE
Biogen, Bayhill, Bayer, Cellgene
MS Journal
I have a patent pending on cytokines and type 1 interferons
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH $01 55997 2010, 2011
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- R. Medori, MD
NONE
NONE
NONE
NONE
NONE
NONE
I am a full time employee of Biogen IDec.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From Biogen Idec (S.E.B., Z.Z., C.C.S., D.C., A.M.B., E.T.W., J.A.D., E.M.V., J.R.R.), Cambridge, MA; Department of Neurology and Neurological Sciences (R.C.A., L.S.), Stanford University, Stanford, CA; and Biogen Idec (R.M.), Zug, Switzerland.
- Correspondence & reprint requests to Dr. Bushnell: steven.bushnell{at}biogenidec.com
Article usage
Cited By...
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Jessica Ailani and Dr. Ailna Masters-Israilov
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Articles
A composite score to predict short-term disease activity in patients with relapsing-remitting MSMaria Pia Sormani, Marco Rovaris, Giancarlo Comi et al.Neurology, September 17, 2007 -
Article
Vitamin D enhances responses to interferon-β in MSXuan Feng, Zhe Wang, Quentin Howlett-Prieto et al.Neurology: Neuroimmunology & Neuroinflammation, October 03, 2019 -
Articles
Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MSF. Sellebjerg, L. Börnsen, M. Khademi et al.Neurology, December 07, 2009 -
Article
Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MSAmanda K. Huber, Lu Wang, Peisong Han et al.Neurology, September 24, 2014